Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Carpenter

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Bulletin of the History of Medicine|May 10, 2011
Bioequivalence: the regulatory career of a pharmaceutical conceptDaniel Carpenter, Dominique A Tobbell
Nature Reviews. Drug Discovery|September 27, 2005
Essay: the political logic of regulatory errorDaniel Carpenter, Michael M Ting
Health Affairs (Project Hope)|September 5, 2023
The Revolving Door In Health Care RegulationGenevieve P Kanter, Daniel Carpenter
The New England Journal of Medicine|June 29, 2011
Reputation and precedent in the bevacizumab decisionDaniel Carpenter, Aaron S Kesselheim, Steven Joffe
Epilepsy & Behavior : E&B|August 17, 2005
Treatment of epilepsy in adults: expert opinion, 2005Steven Karceski, Martha J Morrell, Daniel Carpenter
The New England Journal of Medicine|March 28, 2008
Drug-review deadlines and safety problemsDaniel Carpenter, Evan James Zucker, Jerry Avorn
American Journal of Political Science|March 10, 2012
The complications of controlling agency time discretion: FDA review deadlines and postmarket drug safetyDaniel Carpenter, Jacqueline Chattopadhyay, Susan Moffitt, et al.
Journal of Child Neurology|April 18, 2006
Treatment of pediatric epilepsy: expert opinion, 2005James W Wheless, Dave F Clarke, Daniel Carpenter
Journal of Health Politics, Policy and Law|November 20, 2016
Substantial Equivalence Standards in Tobacco Governance: Statutory Clarity and Regulatory Precedent for the FSPTCADaniel Carpenter, Gregory N Connolly, Lauren Kass Lempert
The New England Journal of Medicine|October 27, 2025
Flaws in the FDA's New Priority Voucher ProgramDaniel Carpenter, Thomas J Hwang, Aaron S Kesselheim
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Bulletin of the History of Medicine|May 10, 2011
Bioequivalence: the regulatory career of a pharmaceutical conceptDaniel Carpenter, Dominique A Tobbell
Nature Reviews. Drug Discovery|September 27, 2005
Essay: the political logic of regulatory errorDaniel Carpenter, Michael M Ting
Health Affairs (Project Hope)|September 5, 2023
The Revolving Door In Health Care RegulationGenevieve P Kanter, Daniel Carpenter
The New England Journal of Medicine|June 29, 2011
Reputation and precedent in the bevacizumab decisionDaniel Carpenter, Aaron S Kesselheim, Steven Joffe
Epilepsy & Behavior : E&B|August 17, 2005
Treatment of epilepsy in adults: expert opinion, 2005Steven Karceski, Martha J Morrell, Daniel Carpenter
The New England Journal of Medicine|March 28, 2008
Drug-review deadlines and safety problemsDaniel Carpenter, Evan James Zucker, Jerry Avorn
American Journal of Political Science|March 10, 2012
The complications of controlling agency time discretion: FDA review deadlines and postmarket drug safetyDaniel Carpenter, Jacqueline Chattopadhyay, Susan Moffitt, et al.
Journal of Child Neurology|April 18, 2006
Treatment of pediatric epilepsy: expert opinion, 2005James W Wheless, Dave F Clarke, Daniel Carpenter
Journal of Health Politics, Policy and Law|November 20, 2016
Substantial Equivalence Standards in Tobacco Governance: Statutory Clarity and Regulatory Precedent for the FSPTCADaniel Carpenter, Gregory N Connolly, Lauren Kass Lempert
The New England Journal of Medicine|October 27, 2025
Flaws in the FDA's New Priority Voucher ProgramDaniel Carpenter, Thomas J Hwang, Aaron S Kesselheim
Pageof 7